Drug
QGC001
QGC001 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 66.7%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
terminated133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins
NCT03198793
terminatedphase_2
QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF
NCT02780180
completedphase_2
Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension
NCT02322450
Clinical Trials (3)
Showing 3 of 3 trials
NCT03198793Phase 2
Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins
NCT02780180Phase 2
QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF
NCT02322450Phase 2
Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3